NewDays Secures $7M To Expand Treatment for Cognitive Impairment, Dementia
NewDays' $7 million seed round was led by General Catalyst and Madrona. The funds will be used to expand into additional states and grow its team.
White matter could have more clues about Alzheimer’s than previously thought, Mount Sinai researchers say
Mount Sinai researchers published a study that could improve neuroscientists’ understanding of the progression of Alzheimer’s and other forms of cognitive decline. It proved that white matter may be a more important region to look at than was previously thought.
presented by
Rethinking The Entry Point to Healthcare in America: Collaboration in Communities
Healthcare in the U.S. today exists in a complex, fragmented and costly system, and the people this system is designed for deserve a holistic approach to best address their individual health needs.
uMETHOD, Getlabs partner to make personalized cognitive decline care plans accessible in Arizona
uMETHOD, which provides precision medicine software to treat cognitive decline, tapped at-home diagnostics provider Getlabs to supply mobile phlebotomies for its patients in Arizona. Blood tests are an essential part of the personalized care plans that uMETHOD provides, and the partnership seeks to make these tests accessible to patients with cognitive decline.
Evidation Health and Eli Lilly study uses Apple devices and apps to predict cognitive impairment
Early results from a study conducted by Evidation Health, Eli Lilly and Apple have shown the ability to detect cognitive decline and mild Alzheimer’s disease using a combination of Apple wearables, mobile devices, digital apps and sleep sensors.
Cognitive health assessment startup Neurotrack raises $21M Series C
The company's platform consists of a digital assessment to measure memory health and an associated program meant to drive better healthy behaviors and training exercises as a way to improve cognitive health.